| Literature DB >> 24127415 |
Nerea Méndez-Barbero1, Vanesa Esteban, Silvia Villahoz, Amelia Escolano, Katia Urso, Arantzazu Alfranca, Cristina Rodríguez, Susana A Sánchez, Tsuyoshi Osawa, Vicente Andrés, José Martínez-González, Takashi Minami, Juan Miguel Redondo, Miguel R Campanero.
Abstract
Atherosclerosis is a complex inflammatory disease involving extensive vascular vessel remodelling and migration of vascular cells. As RCAN1 is implicated in cell migration, we investigated its contribution to atherosclerosis. We show RCAN1 induction in atherosclerotic human and mouse tissues. Rcan1 was expressed in lesional macrophages, endothelial cells and vascular smooth muscle cells and was induced by treatment of these cells with oxidized LDLs (oxLDLs). Rcan1 regulates CD36 expression and its genetic inactivation reduced atherosclerosis extension and severity in Apoe(-/-) mice. This effect was mechanistically linked to diminished oxLDL uptake, resistance to oxLDL-mediated inhibition of macrophage migration and increased lesional IL-10 and mannose receptor expression. Moreover, Apoe(-/-) Rcan1(-/-) macrophages expressed higher-than-Apoe(-/-) levels of anti-inflammatory markers. We previously showed that Rcan1 mediates aneurysm development and that its expression is not required in haematopoietic cells for this process. However, transplantation of Apoe(-/-) Rcan1(-/-) bone-marrow (BM) cells into Apoe(-/-) recipients confers atherosclerosis resistance. Our data define a major role for haematopoietic Rcan1 in atherosclerosis and suggest that therapies aimed at inhibiting RCAN1 expression or function might significantly reduce atherosclerosis burden.Entities:
Keywords: RCAN1; atherosclerosis; hypercholesterolemia; inflammation; macrophage
Mesh:
Substances:
Year: 2013 PMID: 24127415 PMCID: PMC3914525 DOI: 10.1002/emmm.201302842
Source DB: PubMed Journal: EMBO Mol Med ISSN: 1757-4676 Impact factor: 12.137
Figure 1RCAN1-4 is induced in atherosclerotic human and mouse arteries
Figure 2Induction of Rcan1-4 expression by oxLDL Quantitative PCR and representative immunoblot analysis of Rcan1 expression in cells isolated from Apoe mice and treated with 50 µg/ml oxLDL:
Figure 3Rcan1 deficiency decreases atherogenesis burden
Figure 4Rcan1 deficiency results in less-advanced plaques
Figure 5Rcan1 deficiency does not decrease plaque stability
Figure 6Rcan1 mediates macrophage uptake of oxLDL
Figure 7Rcan1 re-expression in Apoe macrophages increases CD36 expression and the uptake of oxLDL Apoe peritoneal macrophages were transduced with lentiviruses encoding GFP or Rcan1-1-IRES-GFP plus Rcan1-4-IRES-GFP.
Figure 8Macrophage migration is inhibited by oxLDL in an Rcan1-dependent manner
Figure 9Increased expression of alternative macrophage polarization markers in Apoe lesions and isolated macrophages
Figure 10Atherosclerosis requires Rcan1 expression in BM-derived cells
Figure 11Model depicting the contribution of Rcan1 to plaque formation Rcan1 mediates expression of the oxLDL receptor CD36 in macrophages, thus regulating oxLDL uptake. Low uptake of oxLDL by Rcan1-deficient macrophages results in macrophage polarization to a phenotype distinct from M1 or M2. These cells display numerous anti-inflammatory features, including high levels of IL10 and MRC1, low levels of MCP1, pronounced phagocytosis activity and weak antigen presentation (Ag pres). However, these macrophages also show increased iNOS expression. Rcan1 ablation also decreases macrophage accumulation, likely by preventing their entrapment and/or the MCP1-mediated recruitment of additional macrophages. The lower accumulation of macrophages in the plaque and their conversion into predominantly anti-inflammatory cells might account for the delayed plaque progression.